Significant progress has been made in ophthalmology, with biopharma companies working on innovative treatments for sight-threatening diseases. As the research accelerates, promising gene therapy, stem cell-based and biopharmaceutical product candidates have progressed into clinical trials. Those innovative next-generation therapies will be welcomed as millions of people around the world suffer from blinding retinal degenerative diseases.